HC Wainwright Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price

TScan Therapeutics (NASDAQ:TCRX - Free Report) had its target price reduced by HC Wainwright from $15.00 to $10.00 in a research report released on Wednesday morning, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for TScan Therapeutics' FY2029 earnings at $0.32 EPS.

Several other analysts also recently issued reports on TCRX. Wedbush reiterated an "outperform" rating and set a $7.00 price target on shares of TScan Therapeutics in a research note on Tuesday. Barclays lowered their price target on TScan Therapeutics from $14.00 to $3.00 and set an "overweight" rating on the stock in a report on Friday, March 7th. Needham & Company LLC reissued a "buy" rating and issued a $9.00 price target on shares of TScan Therapeutics in a research report on Tuesday, April 8th. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $10.00 price objective on shares of TScan Therapeutics in a report on Friday, March 14th. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of "Buy" and an average target price of $8.50.

TScan Therapeutics Stock Down 6.9 %

NASDAQ:TCRX traded down $0.10 during mid-day trading on Wednesday, reaching $1.29. The stock had a trading volume of 244,572 shares, compared to its average volume of 361,475. The stock has a market cap of $72.72 million, a P/E ratio of -1.21 and a beta of 1.06. The business's 50 day moving average is $1.49 and its 200 day moving average is $2.72. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 9.56. TScan Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $9.69.

TScan Therapeutics (NASDAQ:TCRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported ($0.26) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.02. TScan Therapeutics had a negative net margin of 1,188.88% and a negative return on equity of 58.72%. The company had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.62 million. As a group, sell-side analysts predict that TScan Therapeutics will post -1.12 earnings per share for the current year.

Institutional Investors Weigh In On TScan Therapeutics

Large investors have recently made changes to their positions in the company. Prudential Financial Inc. acquired a new position in TScan Therapeutics in the fourth quarter valued at about $32,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of TScan Therapeutics in the 4th quarter worth approximately $32,000. ProShare Advisors LLC acquired a new stake in TScan Therapeutics during the 4th quarter valued at $40,000. Wells Fargo & Company MN raised its position in TScan Therapeutics by 41.1% in the 4th quarter. Wells Fargo & Company MN now owns 19,540 shares of the company's stock valued at $59,000 after purchasing an additional 5,694 shares during the last quarter. Finally, Squarepoint Ops LLC bought a new position in TScan Therapeutics in the 4th quarter valued at $59,000. Institutional investors own 82.83% of the company's stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.